Abbott’s Simcor Significantly Lowers Non-HDL Cholesterol In SEACOAST Phase III Study
This article was originally published in The Pink Sheet Daily
Simcor, with a Feb. 20 user fee date, could face competition from two Merck investigational extended-release niacin combinations, including Cordaptive (laropiprant), with an anticipated FDA action date in Q2 2008.
You may also be interested in...
Solvay will provide sales support in the U.S. in addition to funding development and promotions for the Niaspan/simvastatin combination.
The company announced it has filed the niacin and laropiprant combination, formerly known as MK-0524A.
Combination of niacin and simvastatin will address LDL, HDL and triglycerides in a single pill.